Alterity Therapeutics Limited·Healthcare

Alignment reached on key elements of ATH434 Phase 3 development program Alignment reached on key elements of ATH434 Phase 3 development program

Alterity Therapeutics (NASDAQ: ATHE) outlined its development strategy for lead drug candidate ATH434, highlighting positive Phase II data in multiple system atrophy (MSA), planned regulatory interactions with the U.S. Food and Drug Administration (FDA), and preparations to move into a global Phase III program. Company focus and the unmet need in MSA In the presentation, the

Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) saw a large growth in short interest during the month of February. As of February 27th, there was short interest totaling 19,055 shares, a growth of 69.4% from the February 12th total of 11,249 shares. Currently, 0.4% of the company's stock are short sold.

MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in the Bell Potter Healthcare Horizons Summit taking place 12-13 March 2026 in Sorrento, Australia.

– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies –

Athira Pharma (NASDAQ: ATHA - Get Free Report) and Alterity Therapeutics (NASDAQ: ATHE - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership. Risk and Volatility Athira Pharma has a
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Healthcare
Biotechnology
10
2003-09-29
-0.07